This strategic relationship brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to precision-based clinical oncology trials on a global basis, with the combined solution being deployed to the Microsoft Azure cloud.
PRA is partnering with Deep Lens, Inc. to better integrate technology into clinical trial recruitment. Deep Lens’ award-winning VIPERTM patient screening platform is a breakthrough technology deployed by cancer centers, integrated delivery networks (IDNs), and community oncology networks to identify and match oncology patients who would have otherwise missed the opportunity to enroll in life-saving clinical trials. The differentiated technology and services model allows Deep Lens to deploy its software at cancer centers and site networks on a global basis, free of charge, to give patients better access to the therapies they need and deserve. At the same time, it also provides significant value by accelerating study timelines and bringing game-changing therapies to market sooner.
“More than 14,000 oncology trials are currently recruiting patients, but estimates are that only three to five percent of eligible patients actually participate,” said Kent Thoelke, Chief Scientific Officer at PRA Health Sciences. “The challenges facing clinical trial recruitment are multifaceted, and sponsors have been unable to determine where specific patients are in order to match them to studies—that is about to change. Using Deep Lens’ VIPER technology, the patient identification process will be streamlined by instantly analyzing data within electronic health records, pathology systems, and genomic profiles to enable matching of cancer patients with suitable clinical trials.”
About VIPER Integration
VIPER enables cancer care teams, clinical trial sponsors, and trial coordinators to immediately and automatically match patients based on the genetic profile of their cancers to the best precision therapies and oncology clinical trials. It’s deployed “behind the firewall” at participating sites and automatically ingests data from pathology systems at the time of diagnosis, as well as from electronic medical records and genetic test results from top genetic testing labs around the world. It acts as an AI-driven screening platform for research coordinators and care teams, capturing granular data about patients in their care continuum. VIPER answers a previously unsolvable workflow, helping sponsors identify where patients are in the process, where they may be disqualified, and why they may not have enrolled in a trial once qualified.
Once patients qualify for trials, the VIPER system will refer those patients to PRA’s industry-leading Mobile Health Platform—also deployed to Microsoft Azure—to provide an end-to-end patient-centric screening and trial management experience for providers globally.
The combination of VIPER’s artificial intelligence solution, workflow design, communication optimization, and research coordination services provide sponsors and research sites the best opportunity to connect the right patient to the right trial, at the right time—a true realization of personalized medicine.
“Deep Lens has grown dramatically with unique cloud technology and a business model that takes risk out of its deployment. It has taken the vision of PRA and the maturity of Microsoft to see the potential for this truly unique solution to come to market,” said Simon Arkell, Co-founder and President at Deep Lens. “With global, industry-leading partners like PRA and Microsoft, we expect to exponentially grow our global footprint while dramatically increasing the success rates in oncology research. In turn, this will allow trial sponsors full visibility into the patient screening process so they can get their treatments to market much faster. Together, we will continue our mission to find the right patients for the right trials at the right time.”
“This will really move the needle in cancer research, and it will allow community oncology networks to compete with their much larger competitors at academic medical centers and comprehensive cancer centers,” Thoelke said. “We believe this relationship could create a game-changing model in cancer research, not only for patient screening but for the development of just-in-time networks and other new business models.”
PRA is committed to progress within every stage of clinical research because we believe that through innovation, we will help discover the right treatment for every patient, no matter where they are located. We’re excited to move one step closer to that goal with the help of strategic partners like Deep Lens.
Easing the Rare Disease Patient’s Burden in Clinical Trials with Innovative Technology
In this webinar, you will learn how technology can influence rare disease clinical study design, increase the speed of research and thereby reduce…
Certain challenges within the drug development landscape merit a dedicatedtask force of experts and capabilities. That’s why we built our collection…
State-of-the-art Clinical Facilities
We provide end-to-end bioanalytical support from Pre-clinical to Phase IV studies. At PRA, our laboratories are managed, staffed, and supported by…